Patients with Fabry disease (FD) have a significantly shorter life expectancy compared to the general population, often due to cardiac or renal complications of this rare disease. There are only 2 approved therapies for FD—enzyme replacement therapy and chaperone therapy. Management of FD and its complications is a rapidly evolving field with ongoing developments; from recent guideline recommendations to new data on approved therapies to promising clinical trials on investigational therapies. Timely and proper management is essential to slow progression and avert severe complications. Clinicians who care for patients with FD will receive focused and up-to-date education on managing this rare and complex disease. This activity will be delivered via an innovative online platform and led by faculty experts in FD using virtual small groups of learners to drive discussion and learning through assessments, self-study modules, group tasks, and live group discussions.
There is an urgent and ongoing need to provide cancer care professionals with guidance, training, and support during the COVID-19 pandemic as they respond to unprecedented challenges in maintaining high-quality patient care. Members of the care team are challenged by the rapidly evolving data and recommendations surrounding COVID-19, successfully utilizing telehealth services, and determining how to ensure clinician and team well-being during this difficult time. To successfully overcome these challenges, clinicians who care for patients with cancer must be able to initiate action plans to implement strategies addressing cancer care guidelines and recommendations, organize teams to ensure integration and utilization of telehealth in their oncology practice, and promote practices to support care team well-being during the pandemic. The goal of this educational experience is to establish meaningful, virtual small-group interactions between health care providers that will, through a variety of collaborative educational experiences, help oncology care teams maintain high-quality patient care in light of the pressing demands of the COVID-19 pandemic.
CME/CE Accreditation Information
Insulin is an integral component of diabetes management, providing greater efficacy at lowering HbA1c compared to oral agents. However, average HbA1c levels in patients receiving insulin range from 7.9 to 9.3%, highlighting the need for clinician and patient education to promote proper use of this effective therapy. This Gather-ed educational experience will focus on identifying patient and clinician barriers to insulin initiation and titration and strategies to address these barriers, evaluating efficacy and safety data for insulin, and developing patient-specific plans for insulin therapy.
The goal of this experience is to educate clinicians about caring for patients with tenosynovial giant cell tumor (TGCT). Members of the care team are challenged by the rarity of the disease and determining appropriate treatment approaches. To successfully overcome these challenges, clinicians who care for patients with TGCT must be able to identify patients with TGCT and refer to or partner with tertiary care centers for multidisciplinary management, discuss the benefits and risks of available treatment options for localized and diffuse TGCT, and create a collaborative, individualized TGCT treatment plan.
The goal of this Gather-ed experience is to summarize the latest clinical evidence and recommendations for early diagnosis and aggressive management of MS. This initiative consists of self-study modules and live group discussions that briefly review relevant clinical trial findings and addresses questions clinicians commonly face in their practice.
The goal of this experience is to improve adherence to prophylaxis and management of inhibitors in persons with hemophilia A (PwHA). Members of the hemophilia care team who care for PwHA are challenged by the complexity and rarity of the disease as well as its inherently high treatment burden. To successfully overcome these challenges, clinicians who treat hemophilia must be apprised of the latest data on approved and emerging treatments to facilitate patient and caregiver education, improve adherence, and implement personalized treatment plans that balance treatment efficacy and safety. This educational activity is supported by an educational grant from Genentech.